Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
1 clinical trials · Condition
◉ Watch Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss
| Record | Firm | Date |
|---|---|---|
| Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss (NCT02132130) | Novartis Pharmaceuticals | 2014-06-23 |
Track Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss automatically
Every clearance here is in the API, with alerts when new ones post.